Ongoing clinical trials with ER+ breast cancer in which HCQ and CQ are being combined with standard of care endocrine therapy, an antiestrogen + CDK4/6i, or chemotherapy are listed in Table 2. This evidence concerns the gene ESR1 and breast cancer.